Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2022 | Aug. 10, 2022 | |
Document Information Line Items | ||
Entity Registrant Name | CYNGN INC. | |
Trading Symbol | CYN | |
Document Type | 10-Q | |
Current Fiscal Year End Date | --12-31 | |
Entity Common Stock, Shares Outstanding | 33,627,562 | |
Amendment Flag | false | |
Entity Central Index Key | 0001874097 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Document Period End Date | Jun. 30, 2022 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q2 | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Shell Company | false | |
Entity Ex Transition Period | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity File Number | 001-40932 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 46-2007094 | |
Entity Address, Address Line One | 1015 O’Brien Dr. | |
Entity Address, City or Town | Menlo Park | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94025 | |
City Area Code | (650) | |
Local Phone Number | 924-5905 | |
Title of 12(b) Security | Common stock, $0.00001 | |
Security Exchange Name | NASDAQ | |
Entity Interactive Data Current | Yes |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Current assets | ||
Cash and cash equivalents | $ 5,601,774 | $ 21,945,981 |
Restricted cash | 50,000 | 50,000 |
Short-term investments | 27,000,015 | |
Prepaid expenses and other current assets | 603,508 | 525,304 |
Total current assets | 33,255,297 | 22,521,285 |
Property and equipment, net | 467,671 | 102,787 |
Right of use asset, net | 643,183 | |
Intangible assets, net | 181,880 | 30,917 |
Total Assets | 34,548,031 | 22,654,989 |
Current liabilities | ||
Accounts payable | 243,531 | 112,271 |
Accrued expenses and other current liabilities | 386,605 | 295,156 |
Operating lease liability, current portion | 455,545 | |
Total current liabilities | 1,085,681 | 407,427 |
Operating lease liability, net of current portion | 189,811 | |
Total liabilities | 1,275,492 | 407,427 |
Commitments and contingencies (Note 12) | ||
Stockholders’ Equity | ||
Convertible Series A, B and C preferred stock, Par $0.00001; 10,000,000 shares authorized; none issued and outstanding as of as of June 30, 2022 and December 31, 2021 | ||
Common stock, Par $0.00001; 100,000,000 shares authorized; 33,575,334 and 26,487,680 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | 336 | 265 |
Additional paid-in capital | 158,196,733 | 138,740,827 |
Accumulated deficit | (124,924,530) | (116,493,530) |
Total stockholders’ equity | 33,272,539 | 22,247,562 |
Total Liabilities and Stockholders’ Equity | $ 34,548,031 | $ 22,654,989 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Jun. 30, 2022 | Dec. 31, 2021 |
Common stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 33,575,334 | 26,487,680 |
Common stock, shares outstanding | 33,575,334 | 26,487,680 |
Convertible Series A Preferred Stock | ||
Convertible preferred stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 |
Convertible preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Convertible preferred stock, shares issued | ||
Convertible preferred stock, shares outstanding | ||
Convertible Series B Preferred Stock | ||
Convertible preferred stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 |
Convertible preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Convertible preferred stock, shares issued | ||
Convertible preferred stock, shares outstanding | ||
Convertible Series C Preferred Stock | ||
Convertible preferred stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 |
Convertible preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Convertible preferred stock, shares issued | ||
Convertible preferred stock, shares outstanding |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Income Statement [Abstract] | ||||
Revenue | ||||
Operating expenses: | ||||
Research and development | 2,255,666 | 831,896 | 3,936,811 | 1,766,186 |
General and administrative | 2,357,247 | 1,261,727 | 4,494,763 | 1,877,118 |
Total operating expenses | 4,612,913 | 2,093,623 | 8,431,574 | 3,643,304 |
Loss from operations | (4,612,913) | (2,093,623) | (8,431,574) | (3,643,304) |
Other income (expense), net | ||||
Interest expense, net | (1,607) | (3,901) | (1,986) | (6,043) |
Other income | 2,559 | 5,952 | 2,560 | 5,952 |
Total other income (expense), net | 952 | 2,051 | 574 | (91) |
Net loss | $ (4,611,961) | $ (2,091,572) | $ (8,431,000) | $ (3,643,395) |
Net loss per share attributable to common stockholders’, basic and diluted (in Dollars per share) | $ (0.15) | $ (2.2) | $ (0.29) | $ (3.83) |
Weighted-average shares used in computing net loss per share attributable to common stockholders’, basic and diluted (in Shares) | 30,706,235 | 951,794 | 28,682,245 | 951,794 |
Consolidated Statements of Op_2
Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Income Statement [Abstract] | ||||
Net loss per share attributable to common stockholders’, basic and diluted | $ (0.15) | $ (2.2) | $ (0.29) | $ (3.83) |
Weighted-average shares used in computing net loss per share attributable to common stockholders’, basic and diluted | 30,706,235 | 951,794 | 28,682,245 | 951,794 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) | Convertible Preferred Stock | Common Stock | Additional Paid in Capital | Accumulated Deficit | Total |
Balance at Dec. 31, 2020 | $ 220 | $ 10 | $ 114,291,505 | $ (108,694,001) | $ 5,597,734 |
Balance (in Shares) at Dec. 31, 2020 | 21,982,491 | 951,794 | |||
Stock-based compensation | 96,058 | 96,058 | |||
Net loss | (3,643,395) | (3,643,395) | |||
Balance at Jun. 30, 2021 | $ 220 | $ 10 | 114,387,563 | (112,337,396) | 2,050,397 |
Balance (in Shares) at Jun. 30, 2021 | 21,982,491 | 951,794 | |||
Balance at Mar. 31, 2021 | $ 220 | $ 10 | 114,299,365 | (110,245,824) | 4,053,771 |
Balance (in Shares) at Mar. 31, 2021 | 21,982,491 | 951,794 | |||
Stock-based compensation | 88,198 | 88,198 | |||
Net loss | (2,091,572) | (2,091,572) | |||
Balance at Jun. 30, 2021 | $ 220 | $ 10 | 114,387,563 | (112,337,396) | 2,050,397 |
Balance (in Shares) at Jun. 30, 2021 | 21,982,491 | 951,794 | |||
Balance at Dec. 31, 2021 | $ 265 | 138,740,827 | (116,493,530) | 22,247,562 | |
Balance (in Shares) at Dec. 31, 2021 | 26,487,680 | ||||
Exercise of stock options | $ 6 | 97,652 | 97,658 | ||
Exercise of stock options (in Shares) | 636,041 | ||||
Issuance of common stock and pre-funded warrants in connection with the private placement offering, net of offering costs | $ 38 | 11,989,471 | 11,989,509 | ||
Issuance of common stock and pre-funded warrants in connection with the private placement offering, net of offering costs (in Shares) | 3,790,322 | ||||
Issuance of common warrants at fair value in connection with the private placement | 6,132,436 | 6.132436 | |||
Issuance of common stock upon exercise of pre-funded warrants | $ 27 | 2,635 | 2,662 | ||
Issuance of common stock upon exercise of pre-funded warrants (in Shares) | 2,661,291 | ||||
Stock-based compensation | 1,233,712 | 1,233,712 | |||
Net loss | (8,431,000) | (8,431,000) | |||
Balance at Jun. 30, 2022 | $ 336 | 158,196,733 | (124,924,530) | 33,272,539 | |
Balance (in Shares) at Jun. 30, 2022 | 33,575,334 | ||||
Balance at Mar. 31, 2022 | $ 271 | 139,349,848 | (120,312,569) | 19,037,550 | |
Balance (in Shares) at Mar. 31, 2022 | 27,104,430 | ||||
Exercise of stock options | 8,773 | 8,773 | |||
Exercise of stock options (in Shares) | 19,291 | ||||
Issuance of common stock and pre-funded warrants in connection with the private placement offering, net of offering costs | $ 38 | 11,989,471 | 11,989,509 | ||
Issuance of common stock and pre-funded warrants in connection with the private placement offering, net of offering costs (in Shares) | 3,790,322 | ||||
Issuance of common warrants at fair value in connection with the private placement | 6,132,436 | 6,132,436 | |||
Issuance of common stock upon exercise of pre-funded warrants | $ 27 | 2,635 | 2,662 | ||
Issuance of common stock upon exercise of pre-funded warrants (in Shares) | 2,661,291 | ||||
Stock-based compensation | 713,570 | 713,570 | |||
Net loss | (4,611,961) | (4,611,961) | |||
Balance at Jun. 30, 2022 | $ 336 | $ 158,196,733 | $ (124,924,530) | $ 33,272,539 | |
Balance (in Shares) at Jun. 30, 2022 | 33,575,334 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Cash flows from operating activities | ||
Net loss | $ (8,431,000) | $ (3,643,395) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 229,102 | 45,818 |
Stock-based compensation | 1,233,712 | 96,058 |
Changes in operating assets and liabilities: | ||
Prepaid expenses, operating lease right-of-use assets, and other current assets | (902,512) | (38,329) |
Accounts payable | 131,260 | 57,036 |
Accrued expenses, lease liabilities, and other current liabilities | 736,805 | (61,126) |
Net cash used in operating activities | (7,002,633) | (3,543,938) |
Cash flows from investing activities | ||
Purchase of property and equipment | (410,289) | (7,523) |
Disposal of assets | (4,150) | |
Acquisition of intangible asset | (153,550) | |
Purchase of short-term investments | (27,000,000) | |
Net cash used in investing activities | (27,563,839) | (11,673) |
Cash flows from financing activities | ||
Proceeds from private placement offering, net of offering costs | 18,121,945 | |
Proceeds from exercise of pre-funded warrants | 2,662 | |
Proceeds from Paycheck Protection Program Note | 903,802 | |
Proceeds from exercise of stock options | 97,658 | |
Net cash provided by financing activities | 18,222,265 | 903,802 |
Net decrease in cash and cash equivalents and restricted cash | (16,344,207) | (2,651,809) |
Cash and cash equivalents and restricted cash, beginning of period | 21,995,981 | 6,456,190 |
Cash and cash equivalents and restricted cash, end of period | 5,651,774 | 3,804,381 |
Supplemental disclosure of cash flow: | ||
Cash paid during the period for interest and taxes | ||
Supplemental disclosure of non-cash activities: | ||
Initial recognition of operating lease right-of-use assets and operating lease liabilities | 824,292 | |
Change in deferred rent associated with ASC 842 | 58,676 | |
Acquisition of property and equipment included in accounts payable and accrued expenses | $ 22,185 |
Description of Business
Description of Business | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Description of Business | 1. Description of Business CYNGN Inc., together with its subsidiaries (collectively, “Cyngn” or the “Company”) was incorporated in Delaware in 2013. Cyngn Singapore PTE. LTD., a Singaporean limited company organized in 2015 and Cyngn Philippines, Inc., a Philippines corporation incorporated in 2018 are wholly owned subsidiaries. The Company is headquartered in Menlo Park, CA. Cyngn develops autonomous driving software that can be deployed on multiple vehicle types in various environments. The Company has been operating autonomous vehicles in production environments. Built and tested in difficult and diverse real-world environments, the self-driving system (DriveMod), fleet management system, and Software Development Kit combine to create a full-stack advanced autonomy solution designed to be modular, extendable, and safe. The Company operates one business segment. Initial Public Offering On October 22, 2021, the Company closed its initial public offering (the “IPO”) of 3,500,000 shares of its authorized common stock at an offering price of $7.50 per share. Simultaneously with the closing of the IPO, the common stock began trading on the NASDAQ Capital Market under the symbol “CYN.” The IPO generated net proceeds of $23.3 million after deducting underwriting discounts, commissions and offering expenses. The Company also granted its underwriters the election to exercise a 45-day over-allotment option to purchase an additional 525,000 shares of common stock at the IPO offering price, less underwriting discounts. Simultaneous with the closing of its IPO, the Company also issued 140,000 warrants (the “Purchase Warrant”) to the underwriters. Each Purchase Warrant entitles its holder the option to purchase at a future exercise date, one share of common stock at an initial exercise price of $9.375 per share, subject to certain adjustments and restrictions relating to subsequent resale and transfers. The Purchase Warrants met all the criteria for equity classification. As the Purchase Warrants were equity classified, they do not require subsequent remeasurement after the issuance (see Note 7. Capital Structure). At the completion of the IPO, all shares of the Company’s outstanding redeemable convertible preferred stock automatically converted to shares of common stock (see Note 7. Capital Structure). Immediately after the IPO, the Company filed an amended and restated certificate of incorporation, which became effective on October 22, 2021. The amended and restated certificate of incorporation authorized 110,000,000 shares consisting of 100,000,000 shares of common stock, at a par value of $0.00001, and 10,000,000 shares of preferred stock at a par value of $0.00001. The rights of the holders of common stock are subject to and qualified by rights of the holders of the preferred stock. Private Placement Offering On April 28, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited and institutional investors for a private placement offering (“Private Placement”) of the Company’s common stock (the “Common Stock”) and pre-funded warrants (the “Pre-Funded Warrants”) and warrants exercisable for Common Stock (the “Common Warrants”). Pursuant to the Purchase Agreement, the Company sold (i) 3,790,322 shares of its Common Stock together with Common Warrants to purchase up to 3,790,322 shares of Common Stock, and (ii) 2,661,291 Pre-Funded Warrants with each Pre-Funded Warrant exercisable for one share of Common Stock, together with Common Warrants to purchase up to 2,661,291 shares of Common Stock. The Common Warrants totaled 6,451,613. The Company allocated the proceeds between the Common Stock, Pre-Funded Warrants, and Common Warrants on a relative fair value basis and recorded the amount allocated to the Common Warrants within the additional paid-in capital on the accompanying consolidated balance sheet as the Common Warrants met all the criteria for equity classification. As the Common Warrants were equity classified, they do not require subsequent remeasurement after the issuance (see Note 7. Capital Structure). The Pre-Funded Warrants were exercised in full in May 2022 at a nominal exercise price of $0.001. Each share of Common Stock and accompanying Common Warrant were sold together at a combined offering price of $3.10, and each Pre-Funded Warrant and accompanying Common Warrant were sold together at a combined offering price of $3.09. The Common Warrants have an exercise price of $2.98 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. The Common Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions. There were no Common Warrants exercised as of June 30, 2022 (see Note 7. Capital Structure). The Private Placement closed on April 29, 2022. The Company received gross proceeds of approximately $20 million before deducting transaction related expenses payable by the Company. All qualified legal, accounting, registration and other direct costs related to the Private Placement were offset against the gross proceeds. The Company intends to use the net proceeds to fund its cash needs. Liquidity The Company has incurred losses from operations since inception. The Company incurred net losses of $8.4 million and $3.6 million for the six months ended June 30, 2022 and 2021, respectively. Accumulated deficit amounted to $125.0 million and $116.5 million as of June 30, 2022 and December 31, 2021, respectively. Net cash used in operating activities was $7.0 million and $3.5 million for the six months ended June 30, 2022 and 2021, respectively. The Company’s liquidity is based on its ability to enhance its operating cash flow position, obtain capital financing from equity interest investors and borrow funds to fund its general operations, research and development activities and capital expenditures. The Company’s ability to continue as a going concern is dependent on management’s ability to successfully execute its business plan, which includes increasing revenue while controlling operating costs and expenses to generate positive operating cash flows and obtaining funds from outside sources of financing to generate positive financing cash flows. As of June 30, 2022, the Company’s unrestricted balance of cash and cash equivalents was $5.6 million. As of December 31, 2021, the Company’s unrestricted balance of cash and cash equivalents was $21.9 million. Based on cash flow projections from operating and financing activities and existing balance of cash and cash equivalents, management is of the opinion that the Company has sufficient funds for sustainable operations and it will be able to meet its payment obligations from operations and debt related commitments for at least one year from the issuance date of this report on its consolidated financial statements. Based on the above considerations, the Company’s consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and liquidation of liabilities during the normal course of operations. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated financial statements as of and for the six months ended June 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to applicable rules and regulations of the Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal years ended December 31, 2021, and 2020, which was filed with the SEC on March 24, 2022. The accompanying unaudited consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal years ended December 31, 2021, and 2020, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. There have been no changes to the Company’s significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and 2020 that have had a material impact on the consolidated financial statements and the related notes. The results reported for the interim period presented are not necessarily indicative of results that may be expected for any subsequent quarter or for the full year December 31, 2022. These unaudited consolidated financial statements include all adjustments and accruals that are necessary for a fair statement of all interim periods reported herein. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated upon consolidation. Foreign Currency Translation The functional and reporting currency for Cyngn is the U.S. dollar. Monetary assets and liabilities denominated in currencies other than U.S. dollar are translated into the U.S. dollar at period end rates, income and expenses are translated at the weighted average exchange rates for the period and equity is translated at the historical exchange rates. Foreign currency translation adjustments and transactional gains and losses are immaterial to the consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments include but are not limited to share-based compensation. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company’s cash is placed with high-credit-quality financial institutions and issuers, and at times exceeds federally insured limits. The Company limits its concentration of risk in cash equivalents by diversifying its investments among a variety of industries and issuers. The Company has not experienced any credit loss relating to its cash equivalents. Cash and cash equivalents maintained with domestic commercial banks generally exceed the Federal Deposit Insurance Corporation insurable limit. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. Cyngn invests in U.S. Treasury securities and carries these at amortized cost and recognizes gains and losses when realized. Concentration of Supplier Risk The Company is not currently in the production stage and generally utilizes suppliers for outside development and engineering support. The Company does not believe that there is any significant supplier concentration risk as of June 30, 2022 and December 31, 2021. Cash and Cash Equivalents, Restricted Cash and Short-term Investments The Company considers its bank accounts and all highly liquid investments that are both readily convertible to cash with minimal risk of changes in value due to changes in interest rates, to be cash equivalents. As of June 30, 2022 and December 31, 2021, the Company had $5.6 million and $21.9 million of cash and cash equivalents. In addition, as of June 30, 2022 and December 31, 2021, the Company had $50,000 in restricted cash reported separately as current assets on its consolidated balance sheets. The Company’s restricted cash consists of cash that the Company is obligated to maintain in accordance with the terms of its credit card spending arrangement. The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows: June 30, 2022 2021 Cash and cash equivalents $ 5,601,774 $ 3,404,381 Restricted cash 50,000 400,000 Total cash and cash equivalents and restricted cash $ 5,651,774 $ 3,804,381 The Company considers short-term investments, exclusive of cash equivalents, to include marketable U.S. government securities that it intends to hold until maturity and redeem within one year. The Company treated its U.S. government treasury bill placements as held-to-maturity securities in accordance with the Financial Accounting Standards Board’s (“FASB’) Accounting Standards Codification Topic (“ASC”) 320, “Investments – Debt and Equity Securities” and recorded these at its amortized cost on the accompanying consolidated balance sheet as of June 30, 2022. Fair Value of Financial Instruments The Company complies with the accounting guidance under ASC Topic 820, “Fair Value Measurements” that defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2: Observable inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts of cash equivalents and accounts payable are reasonable estimates of their fair value due to the short-term nature of these accounts. Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Repair and maintenance costs are expensed as incurred. Assets are held as construction work in progress until placed into service, at which date depreciation commences over the estimated useful lives of the respective assets. Depreciation is recorded on a straight-line basis over each asset’s estimated useful life. Property and Equipment Estimated useful lives Computer and equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of 3 years or remaining lease term Automobile 5 years Leases The Company accounts for leases in accordance with ASC Topic 842 (“ASC 842”). All contracts are evaluated to determine whether or not they represent a lease. A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases are classified as finance or operating in accordance with the guidance in ASC 842. The Company does not hold any finance leases. The Company recognized a “right-of-use” asset and lease liability in the consolidated balance sheets under ASC 842 on the office space lease that was amended and renewed in February 2022. On a prospective basis, lease expense will be recognized on a straight-line basis over the remaining term of the lease. Operating leases are recognized on the balance sheet as right-of-use assets, and operating lease liabilities. Upon adoption of ASC 842, the Company elected the “package of practical expedients” which allowed it to not reassess: (a) whether expired or existing other contracts are or contain leases, (b) the lease classification for any expired or existing leases, and (c) the treatment of initial direct costs relating to any existing leases as of the adoption date. The package of practical expedients was made as a single election and was applied to the lease renewed in February 2022. Upon adoption of ASC 842, the Company also elected the practical expedient to not separate non-lease components, such as common area maintenance, from associated lease components for its ground and office space leases (see Note 4. Leases). Long-Lived Assets and Finite Lived Intangibles The Company has finite lived intangible assets consisting of patents and trademarks. These assets are amortized on a straight-line basis over their estimated remaining economic lives. The patents and trademarks are amortized over 15 years. On April 1, 2022, the Company entered into an agreement for exclusive rights to certain hardware and software products and the rights to subsequently sell the software products and accompanying services. The Company paid a purchase price of $100,000 for these rights. The Company evaluated if substantially all of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets to determine if the transaction should be accounted for as an asset acquisition. Since the only substantive assets acquired pertained to rights to the intellectual property, the entire purchase price was allocated to intellectual property and accounted for as intangible assets with a useful life of 15 years. In accordance with ASC 805-50, Business Combination The Company reviews its long-lived assets and finite lived intangibles for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The events and circumstances the Company monitors and considers include significant decreases in the market price of similar assets, significant adverse changes to the extent and manner in which the asset is used, an adverse change in legal factors or business climate, an accumulation of costs that exceed the estimated cost to acquire or develop a similar asset, and continuing losses that exceed forecasted costs. The Company assesses the recoverability of these assets by comparing the carrying amount of such assets or asset group to the future undiscounted cash flow it expects the assets or asset group to generate. The Company recognizes an impairment loss if the sum of the expected long-term undiscounted cash flows that the long-lived asset is expected to generate is less than the carrying amount of the long-lived asset being evaluated. An impairment charge would then be recognized equal to the amount by which the carrying amount exceeds the fair value of the asset. Income Taxes The Company accounts for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance as of June 30, 2022 and December 31, 2021 (see Note 11. Income Taxes). There are no uncertain tax positions that would require recognition in the financial statements. If the Company were to incur an income tax liability in the future, interest on any income tax liability would be reported as interest expense and penalties on any income tax would be reported as income taxes. Management’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of or changes in tax laws, regulations and interpretations thereof as well as other factors. Stock-based Compensation The Company recognizes the cost of share-based awards granted to employees and directors based on the estimated grant-date fair value of the awards. Cost is recognized on a straight-line basis over the service period, which is generally the vesting period of the award. The Company recognizes stock-based compensation cost and reverses previously recognized costs for unvested awards in the period forfeitures occur. The Company determines the fair value of stock options using the Black-Scholes option pricing model, which is impacted by the fair value of common stock, expected price volatility of common stock, expected term, risk-free interest rates, and expected dividend yield. Net Loss Per Share Attributable to Common Stockholders The Company computes loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the shares (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding (see Note 8. Net Loss per Share Attributable to Common Stockholders). Revenue Recognition The Company has not generated any revenues for the three months ended June 30, 2022 and 2021, and the six months ended June 30, 2022 and 2021. Recent Accounting Standards There were no significant updates to the recently issued accounting standards. Although there are several other new accounting standards issued or proposed by the FASB, the Company does not believe any of those accounting standards have had or will have a material impact on its financial position or operating results. |
Balance Sheet Components
Balance Sheet Components | 6 Months Ended |
Jun. 30, 2022 | |
Balance Sheet Components [Abstract] | |
Balance Sheet Components | 3. Balance Sheet Components Fair value of Financial Instruments The following table summarizes the Company’s fair value hierarchy for its financial assets measured at fair value on a recurring basis as of June 30, 2022 and December 31, 2021. In addition to its cash and cash equivalents, the Company’s short-term investments consisted of U.S. government treasury bills whose fair values are determined by Level 1 inputs utilizing quoted prices in active markets for identical assets: Level 1 Level 2 Level 3 Total June 30, 2022 Cash and cash equivalents Cash at banks $ 5,651,774 $ - $ - $ 5,651,774 Short-term investments, net U.S. government securities 26,958,781 1 - - 26,958,781 Total $ 32,610,555 $ - $ - $ 32,610,555 1 Stated at fair values, net of unrealized holding (loss) of $41,233 and dividends of $15. Level 1 Level 2 Level 3 Total December 31, 2021 Cash and cash equivalents Cash at banks $ 21,995,981 $ - $ - $ 21,995,981 Total $ 21,995,981 $ - $ - $ 21,995,981 There were no transfers between Level 1, Level 2, or Level 3 financial instruments in the three months ended June 30, 2022 and 2021, and in the six months ended June 30, 2022 and 2021. The Company held no recurring financial liabilities as of June 30, 2022 or December 31, 2021. Property and Equipment Property and equipment is comprised of the following: ( Unaudited) December 31, 2022 2021 Automobiles $ 361,724 $ 279,617 Furniture and fixtures 139,501 133,102 Computer and equipment 276,257 76,048 Construction work in progress 121,574 - Property and equipment, gross 899,056 488,767 Less: accumulated depreciation (431,385 ) (385,980 ) Total property and equipment, net $ 467,671 $ 102,787 Depreciation expense for the three months ended June 30, 2022 and 2021 was $24,330 and $22,044, respectively, and for the six months ended June 30, 2022 and 2021 was $45,405 and $44,086, respectively. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: ( Unaudited) December 31, 2022 2021 Credit card payable $ 6,750 $ 11,678 Accrued expenses 138,734 82,478 Accrued payroll 241,121 201,000 Total accrued expenses and other current liabilities $ 386,605 $ 295,156 On March 27, 2020, the United States Congress passed the Coronavirus, Aid, Relief and Economic Security Act (the “CARES Act”) in response to the economic impact of the coronavirus (“COVID-19”) pandemic in the United States (see Note 13. Risks and Uncertainties). Section 2302 of the CARES Act allowed employers to defer the deposit and payment of the employer’s share of social security taxes that were otherwise required to be deposited between March 27 and December 31, 2020, and to pay the deferred taxes in two installments — with the first half due on December 31, 2021, and the remainder by December 31, 2022. As of December 31, 2021, the Company remitted $67,958 in social security taxes due that were deferred between May 1 and December 31, 2020. The remaining $67,958 is expected to be paid prior to December 31, 2022. Section 2301 of the CARES Act also provided refundable employee retention credits (the “ERC”) against certain employment taxes. The Company is currently evaluating its eligibility to claim the ERC and the impact of the credits on its consolidated statement of operations. |
Leases
Leases | 6 Months Ended |
Jun. 30, 2022 | |
Leases [Abstract] | |
Leases | 4. Leases The Company leases its office space in Menlo Park, California, under a lease agreement which expired in February 2022 and was subsequently renewed and amended for an 18 month term that expires in August 2023. Monthly payments are approximately $47,000. The lease includes non-lease components (i.e. common area maintenance costs) that are paid separately from rent based on actual costs incurred. The Company’s future lease payments under non-cancellable leases as of June 30, 2022 are as follows, which are presented as lease liabilities on the Company’s consolidated balance sheet: Period Operating Remainder of 2022 $ 279,410 2023 382,326 Total lease payments 661,736 Less: imputed interest (16,380 ) Present value of lease liabilities $ 645,356 Operating lease liability, current $ 455,545 Operating lease liability, net of current portion 189,811 Total operating lease liabilities $ 645,356 Weighted-average remaining lease term (in years) 1.17 Weighted-average discount rate 3.44 % Lease expense under the Company’s operating lease was $157,869 and $75,287 for the three months ended June 30, 2022 and 2021, respectively, and $235,968 and $114,882 for the six months ended June 30, 2022 and 2021, respectively. The amortization of the operating lease right-of-use assets totaled $133,998 and $0 for the three months ended June 30, 2022 and 2021, respectively, and $181,110 and $0 for the six months ended June 30, 2022 and 2021, respectively. |
Intangible Assets, Net
Intangible Assets, Net | 6 Months Ended |
Jun. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets, Net | 5. Intangible Assets, Net The gross carrying amount and accumulated amortization of separately identifiable intangible assets are as follows: As of June 30, 2022 Gross Accumulated Net Carrying Patents $ 60,550 $ (4,614 ) $ 55,936 Trademark 45,000 (18,500 ) 26,500 Rights to intellectual property 100,000 (556 ) 99,444 Total intangible assets $ 205,550 $ (23,670 ) $ 181,880 As of December 31, 2021 Gross Accumulated Net Carrying Patent $ 7,000 $ (4,083 ) $ 2,917 Trademark 45,000 (17,000 ) 28,000 Total intangible assets $ 52,000 $ (21,083 ) $ 30,917 Amortization expense for the three months ended June 30, 2022 and 2021 was $1,720 and $866, respectively, and for the six months ended June 30, 2022 and 2021 was $2,587 and $1,733, respectively. Estimated amortization expense for all intangible assets subject to amortization in future years is expected to be: Years Ending December 31, Amortization Remainder of 2022 $ 6,852 2023 10,688 2024 10,688 2025 10,688 2026 10,688 Thereafter 132,276 Total $ 181,880 |
Debt
Debt | 6 Months Ended |
Jun. 30, 2022 | |
Debt [Abstract] | |
Debt | 6. Debt Paycheck Protection Program Note In April 2020, the Company entered into a Note with JPMorgan Chase (the “Lender”) under the U.S. Small Business Administration (“SBA”) Paycheck Protection Program (“PPP”) established under Section 1102 of the CARES Act, pursuant to which the Company borrowed $695,078 (the “Note”). The Note accrues interest at a rate of 0.98% per annum and matures in 24 months from the date of the Note. The Note may be repaid at any time with no prepayment penalty. All of the funds received under the PPP had been used for qualified purposes. The Company applied for forgiveness of the Note in accordance with PPP guidelines, and in October, 2021, received approval of the forgiveness application. As of June 30, 2022 and December 31, 2021, there was no outstanding balance for the Note. In February 2021, the Company entered into a second Note (the “PPP2 Note”) with the Lender, pursuant to which the Lender agreed to make a loan to the Company under the PPP offered by the SBA in a principal amount of $892,115 pursuant to Title 1 of the CARES Act. The PPP2 Note matures in five years with interest accruing at 0.98% per annum. Proceeds of the PPP2 Note are available to be used to pay for payroll costs, including salaries, commissions, and similar compensation, group health care benefits, and paid leaves; rent; utilities; and interest on certain other outstanding debt. All of the funds received under the PPP2 Note were used for qualified purposes during 2021. The Company applied for forgiveness of the loan in accordance with PPP guidelines, and in November, 2021, received approval of the forgiveness application. As of June 30, 2022 and December 31, 2021, there was no outstanding balance for the PPP2 Note. |
Capital Structure
Capital Structure | 6 Months Ended |
Jun. 30, 2022 | |
Capital Structure [Abstract] | |
Capital Structure | 7. Capital Structure Common Stock As of June 30, 2022 and December 31, 2021, the Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.00001 per share. As of June 30, 2022 and December 31, 2021, the Company had 33,575,334 and 26,487,680 shares of common stock issued and outstanding, respectively. Holders of common stock have no preemptive, conversion or subscription rights and there is no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future. Warrants The following warrants were outstanding as of June 30, 2022, all of which contain standard anti-dilution protections in the event of subsequent rights offerings, stock splits, stock dividends or other extraordinary dividends, or other similar changes in the Company’s common stock or capital structure, and none of which have any participating rights for any losses: Securities into which warrants are convertible Warrants Exercise Expiration Fair Common stock (Initial Public Offering) 140,000 $ 9.375 October 2026 $ 170,397 Common stock (Private Placement) 6,451,613 $ 2.98 April 2027 $ 6,132,436 Total 6,591,613 $ 6,302,833 The Company accounts for warrants in accordance with ASC 480, Distinguishing Liabilities from Equity The Company used the following assumptions: Initial Public Offering Private Placement Warrants Warrants Fair value of underlying securities $ 2.88 $ 1.37 Expected volatility 51.0 % 45.0 % Expected term (in years) 5.0 5.0 Risk-free interest rate 1.13 % 2.92 % Convertible Preferred Stock In October 2021, the Company amended its Certificate of Incorporation and revised the number of preferred stock shares authorized for issuance to 10,000,000 shares at a par value of $0.00001. As of June 30, 2022, there were no shares issued and outstanding against these shares. Conversion The Company’s convertible preferred stock shares that were outstanding at the completion of the IPO on October 20, 2021 automatically converted to shares of common stock on a 1:1 basis. Prior to the completion of the IPO, the Company was authorized to issue up to 21,982,491 shares of preferred stock at a par value of $0.00001. The authorized, issued and outstanding shares of the convertible preferred stock and liquidation preferences prior to the IPO were as follows: Series Shares Shares Per Share Aggregate Gross Series A 10,157,843 10,157,843 0.6842 6,949,996 6,949,996 Series B 6,567,670 6,567,670 3.3939 22,290,015 22,290,015 Series C 5,256,978 5,256,978 15.7933 83,025,031 83,025,031 21,982,491 21,982,491 112,265,042 112,265,042 Dividends The holders of preferred stock are entitled to receive dividends, when and if declared by the Company’s Board of Directors, out of any legally available funds. The holders of preferred stock are entitled to receive dividends, prior and in preference to dividends declared on common stock, at the rate of: Series A - $0.0411 per share per annum; Series B - $0.2036 per share per annum; and Series C - $0.9476 per share per annum. Dividends are non-cumulative and will be paid pro rata, on an equal priority, pari passu basis. After payment of preferred stock dividends, any additional dividends will be paid ratably among holders of common stock and preferred stock on an as converted to Common Stock basis. As of June 30, 2022 and December 31, 2021, no dividends have been declared. Voting The holder of each share of Preferred Stock is entitled to voting rights equal to the number of shares of common stock. Preferred stockholders shall cast the number of votes equal to the number of whole shares of common stock into which the shares of Preferred Stock held by such holder are convertible. So long as any shares of Series A Preferred Stock remain outstanding, the holders of the Series A Preferred Stock, voting as a separate class, are entitled to elect one director of the Company. So long as any shares of Series B Preferred Stock remain outstanding, the holders of the Series B Preferred Stock, voting as a separate class, are entitled to elect one director of the Company. So long as any shares of Series C Preferred Stock remain outstanding, the holders of the Series C Preferred Stock, voting as a separate class, are entitled to elect one director of the Company. The holders of Common Stock, voting as a separate class, are entitled to elect two directors of the Company. The holders of Preferred Stock and Common Stock, on an as converted to basis, are entitled to elect any remaining members to the Board of Directors. |
Net Loss Per Share Attributable
Net Loss Per Share Attributable to Common Stockholders | 6 Months Ended |
Jun. 30, 2022 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share Attributable to Common Stockholders | 8. Net Loss Per Share Attributable to Common Stockholders The following table summarizes the computation of basic and diluted loss per share: Three months ended 2022 2021 Net loss attributable to common stockholders $ (4,611,961 ) $ (2,091,572 ) Basic and diluted weighted average common shares outstanding 30,706,235 951,794 Loss per share: Basic and diluted $ (0.15 ) $ (2.20 ) Six months ended 2022 2021 Net loss attributable to common stockholders $ (8,431,000 ) $ (3,643,395 ) Basic and diluted weighted average common shares outstanding 26,682,245 951,794 Loss per share: Basic and diluted $ (0.29 ) $ (3.83 ) Basic loss per share is based upon the weighted average number of shares of common stock outstanding during the period. Diluted loss per share would include the effect of unvested restricted stock awards and the convertible preferred Stock; however, such items were not considered in the calculation of the diluted weighted average common shares outstanding since they would be anti-dilutive. Common stock reserved for future issuance, on an as-if converted basis, are shown below as of: June 30, 2022 2021 Issuance of options under stock option plan 9,708,436 5,923,887 Shares available for future stock option grants 8,911,339 10,877,419 Common shares issuable upon conversion of preferred stock - 21,982,491 Total 18,619,775 38,783,797 |
Stock-Based Compensation Expens
Stock-Based Compensation Expense | 6 Months Ended |
Jun. 30, 2022 | |
Stock-Based Compensation Expense [Abstract] | |
Stock-based Compensation Expense | 9. Stock-based Compensation Expense Stock-Based Compensation The Company measures employee and director stock-based compensation awards based on the award’s estimated fair value on the date of grant. Expense associated with these awards is recognized using the straight-line attribution method over the requisite service period for stock options, restricted stock units (“RSUs”) and restricted stock, and is reported in our consolidated statements of comprehensive loss. The fair value of the Company’s stock options is estimated, using the Black-Scholes option-pricing model. The resulting fair value is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award. The Company has elected to recognize forfeitures as they occur. Stock options generally vest over four years and have a contractual term of ten years. Determining the grant date fair value of options requires management to make assumptions and judgments. These estimates involve inherent uncertainties and if different assumptions had been used, stock-based compensation expense could have been materially different from the amounts recorded. The assumptions and estimates for valuing stock options are as follows: ● Fair value per share of Company’s common stock. ● Expected volatility. ● Expected term. Staff Accounting Bulletin, Topic 14 ● Risk-free interest rate. ● Estimated dividend yield. Equity Incentive Plans In February 2013, the Company’s Board of Directors adopted the 2013 Equity Incentive Plan (the “2013 Plan”). The 2013 Plan authorizes the award of stock options, stock appreciation rights, restricted stock awards, stock appreciation rights, RSUs, performance awards, and other stock or cash awards. In October 2021, the Company’s Board of Directors adopted the Cyngn Inc. 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan replaces the 2013 Plan. However, awards outstanding under the 2013 Plan will continue to be governed by their existing terms. As of June 30, 2022 and December 31, 2021, approximately 8,911,339 and 10,502,696 shares of common stock were reserved and available for issuance under the 2021 Plan and 2013 Plan, respectively. Options issued under the Plan generally vest based on continuous service provided by the option holder over a four-year period. Compensation expense related to these options is recognized on a straight-line basis over the four-year period based upon the fair value at the grant date. The following table summarizes information about the Company’s stock options outstanding as well as stock options vested and exercisable as of June 30, 2022, and activity during the six months then ended: Shares Weighted- Weighted- Aggregate Outstanding as of December 31, 2021 8,769,694 $ 1.20 7.15 $ 15,746,916 Granted 1,384,500 1.95 - Exercised (636,041 ) 0.15 - 931,660 Cancelled/forfeited (50,209 ) 2.88 - Outstanding as of June 30, 2022 9,467,944 $ 1.37 7.20 $ 5,082,634 Vested and expected to vest at June 30, 2022 9,467,944 $ 1.37 7.20 $ 5,082,634 Vested and exercisable at June 30, 2022 5,409,688 $ 0.37 5.63 $ 5,019,382 The following table summarizes information about the Company’s RSUs as of June 30, 2022, and activity during the six months then ended: Shares Weighted- Unvested shares at December 31, 2021 - $ - RSUs granted 244,566 5.52 RSUs vested (4,074 ) 5.52 RSUs forfeited - - Unvested Shares at June 30, 2022 240,492 $ 5.52 The fair value of a stock option is estimated using an option-pricing model that takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the expected term of the option. The Company has used the simplified method in calculating the expected term of all option grants based on the vesting period and contractual term. Compensation costs related to share-based payment transactions are recognized in the financial statements upon satisfaction of the requisite service or vesting requirements. The weighted average per share grant-date fair value of options granted during the six months ended June 30, 2022 and 2021 was $0.77 and $0, respectively. The following weighted average assumptions were used in estimating the grant date fair values during the: Six Months Ended 2022 2021 Fair value of common stock $ 1.95 $ - Expected term (in years) 6.06 - Risk-free rate 2.49 % - % Expected volatility 36.23 % - % Dividend yield 0 % 0 % We recorded stock-based compensation expense from stock options and RSUs of approximately $713,570 and $88,198, during the three months ended June 30, 2022 and 2021, respectively, and $1,233,712 and $96,058, during the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, total unrecognized stock-based compensation cost related to outstanding unvested stock options and unvested RSUs that are expected to vest was $8,112,136. This unrecognized stock-based compensation cost is expected to be recognized over a weighted-average period of approximately 3.7 years. |
Retirement Savings Plan
Retirement Savings Plan | 6 Months Ended |
Jun. 30, 2022 | |
Retirement Savings Plan [Abstract] | |
Retirement Savings Plan | 10. Retirement Savings Plan Effective November 17, 2017, the Company established the Cyngn Inc. 401(k) Plan for the exclusive benefit of all eligible employees and their beneficiaries with the intention to provide a measure of retirement security for the future. This plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA) and qualifies under Section 401(k) of the Internal Revenue Code. Cyngn Inc. did not offer and has not provided a company match for its 401(k) Plan. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 11. Income Taxes For the three and six months ended June 30, 2022 and 2021, the Company recorded income tax expense of $0. The effective tax rate is 0% for the three and six months ended June 30, 2022 and 2021. For financial reporting purposes, the Company’s effective tax rate used for the interim periods is based on the estimated full-year income tax rate. For the three and six months ended June 30, 2022, the Company’s effective tax rate differs from the statutory rate, primarily due to a valuation allowance recorded against the net deferred tax asset balance. On March 27, 2020, the CARES Act was enacted in response to market conditions related to the COVID-19 pandemic. The CARES Act includes many measures to help companies, including changes that are temporary and non-income based tax laws, some of which were part of the Tax Cuts and Jobs Act. One provision of the CARES Act increases the tax deduction for net operating losses from 80% to 100% for 2018 through 2020 and allows net operating losses generated in 2018 through 2020 to be carried back up to five years. The Company has made reasonable assessments in accounting for certain effects of the CARES Act that was passed. However, the provisional impacts may be refined over the prescribed measurement period. Currently, the Company is not under examination by any taxing authority. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 12. Commitments and Contingencies Legal Proceedings The Company is subject to legal and regulatory actions that arise from time to time. The assessment as to whether a loss is probable or reasonably possible, and as to whether such loss or a range of such loss is estimable, often involves significant judgment about future events, and the outcome of litigation is inherently uncertain. There is no material pending or threatened litigation against the Company that remains outstanding as of June 30, 2022 and 2021. |
Risks and Uncertainties
Risks and Uncertainties | 6 Months Ended |
Jun. 30, 2022 | |
Risks and Uncertainties [Abstract] | |
Risks and Uncertainties | 13. Risks and Uncertainties The Company’s business operations, operating results, and financial condition are vulnerable to certain risks and uncertainties including: ● Inflation and its related impact on costs and expenditures on domestic and foreign-sourced materials and services; ● Rising interest rates and its impact on the equity markets, investment valuations, and interest rate-sensitive calculations such as discount rate assumptions used in cash flow projections and going-concern assessments; ● Effects of the Russia-Ukraine conflict such as possible cyberattacks and potential disruptions in the banking systems and capital market and the supply chain; ● Other factors beyond its control such as natural disasters, terrorism, civil unrest, infectious diseases and pandemics including COVID-19 and its variants The Company is unable to predict and quantify at this time the extent of the related potential adverse effects but continuously monitors these risks and uncertainties on its future operations and financial performance. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | 14. Subsequent Events The Company performed a review of events subsequent to the balance sheet date through the date the financial statements were issued and determined that there were no other events requiring recognition or disclosure in the financial statements. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited consolidated financial statements as of and for the six months ended June 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to applicable rules and regulations of the Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal years ended December 31, 2021, and 2020, which was filed with the SEC on March 24, 2022. The accompanying unaudited consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal years ended December 31, 2021, and 2020, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. There have been no changes to the Company’s significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and 2020 that have had a material impact on the consolidated financial statements and the related notes. The results reported for the interim period presented are not necessarily indicative of results that may be expected for any subsequent quarter or for the full year December 31, 2022. These unaudited consolidated financial statements include all adjustments and accruals that are necessary for a fair statement of all interim periods reported herein. |
Principles of Consolidation | Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated upon consolidation. |
Foreign Currency Translation | Foreign Currency Translation The functional and reporting currency for Cyngn is the U.S. dollar. Monetary assets and liabilities denominated in currencies other than U.S. dollar are translated into the U.S. dollar at period end rates, income and expenses are translated at the weighted average exchange rates for the period and equity is translated at the historical exchange rates. Foreign currency translation adjustments and transactional gains and losses are immaterial to the consolidated financial statements. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments include but are not limited to share-based compensation. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company’s cash is placed with high-credit-quality financial institutions and issuers, and at times exceeds federally insured limits. The Company limits its concentration of risk in cash equivalents by diversifying its investments among a variety of industries and issuers. The Company has not experienced any credit loss relating to its cash equivalents. Cash and cash equivalents maintained with domestic commercial banks generally exceed the Federal Deposit Insurance Corporation insurable limit. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. Cyngn invests in U.S. Treasury securities and carries these at amortized cost and recognizes gains and losses when realized. |
Concentration of Supplier Risk | Concentration of Supplier Risk The Company is not currently in the production stage and generally utilizes suppliers for outside development and engineering support. The Company does not believe that there is any significant supplier concentration risk as of June 30, 2022 and December 31, 2021. |
Cash and Cash Equivalents , Restricted Cash and Short-term Investments | Cash and Cash Equivalents, Restricted Cash and Short-term Investments The Company considers its bank accounts and all highly liquid investments that are both readily convertible to cash with minimal risk of changes in value due to changes in interest rates, to be cash equivalents. As of June 30, 2022 and December 31, 2021, the Company had $5.6 million and $21.9 million of cash and cash equivalents. In addition, as of June 30, 2022 and December 31, 2021, the Company had $50,000 in restricted cash reported separately as current assets on its consolidated balance sheets. The Company’s restricted cash consists of cash that the Company is obligated to maintain in accordance with the terms of its credit card spending arrangement. The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows: June 30, 2022 2021 Cash and cash equivalents $ 5,601,774 $ 3,404,381 Restricted cash 50,000 400,000 Total cash and cash equivalents and restricted cash $ 5,651,774 $ 3,804,381 The Company considers short-term investments, exclusive of cash equivalents, to include marketable U.S. government securities that it intends to hold until maturity and redeem within one year. The Company treated its U.S. government treasury bill placements as held-to-maturity securities in accordance with the Financial Accounting Standards Board’s (“FASB’) Accounting Standards Codification Topic (“ASC”) 320, “Investments – Debt and Equity Securities” and recorded these at its amortized cost on the accompanying consolidated balance sheet as of June 30, 2022. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company complies with the accounting guidance under ASC Topic 820, “Fair Value Measurements” that defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2: Observable inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts of cash equivalents and accounts payable are reasonable estimates of their fair value due to the short-term nature of these accounts. |
Property and Equipment | Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Repair and maintenance costs are expensed as incurred. Assets are held as construction work in progress until placed into service, at which date depreciation commences over the estimated useful lives of the respective assets. Depreciation is recorded on a straight-line basis over each asset’s estimated useful life. Property and Equipment Estimated useful lives Computer and equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of 3 years or remaining lease term Automobile 5 years |
Leases | Leases The Company accounts for leases in accordance with ASC Topic 842 (“ASC 842”). All contracts are evaluated to determine whether or not they represent a lease. A lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases are classified as finance or operating in accordance with the guidance in ASC 842. The Company does not hold any finance leases. The Company recognized a “right-of-use” asset and lease liability in the consolidated balance sheets under ASC 842 on the office space lease that was amended and renewed in February 2022. On a prospective basis, lease expense will be recognized on a straight-line basis over the remaining term of the lease. Operating leases are recognized on the balance sheet as right-of-use assets, and operating lease liabilities. Upon adoption of ASC 842, the Company elected the “package of practical expedients” which allowed it to not reassess: (a) whether expired or existing other contracts are or contain leases, (b) the lease classification for any expired or existing leases, and (c) the treatment of initial direct costs relating to any existing leases as of the adoption date. The package of practical expedients was made as a single election and was applied to the lease renewed in February 2022. Upon adoption of ASC 842, the Company also elected the practical expedient to not separate non-lease components, such as common area maintenance, from associated lease components for its ground and office space leases (see Note 4. Leases). |
Long-Lived Assets and Finite Lived Intangibles | Long-Lived Assets and Finite Lived Intangibles The Company has finite lived intangible assets consisting of patents and trademarks. These assets are amortized on a straight-line basis over their estimated remaining economic lives. The patents and trademarks are amortized over 15 years. On April 1, 2022, the Company entered into an agreement for exclusive rights to certain hardware and software products and the rights to subsequently sell the software products and accompanying services. The Company paid a purchase price of $100,000 for these rights. The Company evaluated if substantially all of the assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets to determine if the transaction should be accounted for as an asset acquisition. Since the only substantive assets acquired pertained to rights to the intellectual property, the entire purchase price was allocated to intellectual property and accounted for as intangible assets with a useful life of 15 years. In accordance with ASC 805-50, Business Combination The Company reviews its long-lived assets and finite lived intangibles for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The events and circumstances the Company monitors and considers include significant decreases in the market price of similar assets, significant adverse changes to the extent and manner in which the asset is used, an adverse change in legal factors or business climate, an accumulation of costs that exceed the estimated cost to acquire or develop a similar asset, and continuing losses that exceed forecasted costs. The Company assesses the recoverability of these assets by comparing the carrying amount of such assets or asset group to the future undiscounted cash flow it expects the assets or asset group to generate. The Company recognizes an impairment loss if the sum of the expected long-term undiscounted cash flows that the long-lived asset is expected to generate is less than the carrying amount of the long-lived asset being evaluated. An impairment charge would then be recognized equal to the amount by which the carrying amount exceeds the fair value of the asset. |
Income Taxes | Income Taxes The Company accounts for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance as of June 30, 2022 and December 31, 2021 (see Note 11. Income Taxes). There are no uncertain tax positions that would require recognition in the financial statements. If the Company were to incur an income tax liability in the future, interest on any income tax liability would be reported as interest expense and penalties on any income tax would be reported as income taxes. Management’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of or changes in tax laws, regulations and interpretations thereof as well as other factors. |
Stock-based Compensation | Stock-based Compensation The Company recognizes the cost of share-based awards granted to employees and directors based on the estimated grant-date fair value of the awards. Cost is recognized on a straight-line basis over the service period, which is generally the vesting period of the award. The Company recognizes stock-based compensation cost and reverses previously recognized costs for unvested awards in the period forfeitures occur. The Company determines the fair value of stock options using the Black-Scholes option pricing model, which is impacted by the fair value of common stock, expected price volatility of common stock, expected term, risk-free interest rates, and expected dividend yield. |
Net Loss Per Share Attributable to Common Stockholders | Net Loss Per Share Attributable to Common Stockholders The Company computes loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the shares (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding (see Note 8. Net Loss per Share Attributable to Common Stockholders). |
Revenue Recognition | Revenue Recognition The Company has not generated any revenues for the three months ended June 30, 2022 and 2021, and the six months ended June 30, 2022 and 2021. |
Recent Accounting Standards | Recent Accounting Standards There were no significant updates to the recently issued accounting standards. Although there are several other new accounting standards issued or proposed by the FASB, the Company does not believe any of those accounting standards have had or will have a material impact on its financial position or operating results. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Schedule of cash and cash equivalents and restricted cash | June 30, 2022 2021 Cash and cash equivalents $ 5,601,774 $ 3,404,381 Restricted cash 50,000 400,000 Total cash and cash equivalents and restricted cash $ 5,651,774 $ 3,804,381 |
Schedule of cash and cash equivalents and restricted cash | Property and Equipment Estimated useful lives Computer and equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of 3 years or remaining lease term Automobile 5 years |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Balance Sheet Components [Abstract] | |
Schedule of level 1 inputs utilizing quoted prices in active markets for identical assets | Level 1 Level 2 Level 3 Total June 30, 2022 Cash and cash equivalents Cash at banks $ 5,651,774 $ - $ - $ 5,651,774 Short-term investments, net U.S. government securities 26,958,781 1 - - 26,958,781 Total $ 32,610,555 $ - $ - $ 32,610,555 Level 1 Level 2 Level 3 Total December 31, 2021 Cash and cash equivalents Cash at banks $ 21,995,981 $ - $ - $ 21,995,981 Total $ 21,995,981 $ - $ - $ 21,995,981 |
Schedule of property and equipment | ( Unaudited) December 31, 2022 2021 Automobiles $ 361,724 $ 279,617 Furniture and fixtures 139,501 133,102 Computer and equipment 276,257 76,048 Construction work in progress 121,574 - Property and equipment, gross 899,056 488,767 Less: accumulated depreciation (431,385 ) (385,980 ) Total property and equipment, net $ 467,671 $ 102,787 |
Schedule of accrued expenses and other current liabilities | ( Unaudited) December 31, 2022 2021 Credit card payable $ 6,750 $ 11,678 Accrued expenses 138,734 82,478 Accrued payroll 241,121 201,000 Total accrued expenses and other current liabilities $ 386,605 $ 295,156 |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Leases [Abstract] | |
Schedule of future lease payments under non-cancellable leases | Period Operating Remainder of 2022 $ 279,410 2023 382,326 Total lease payments 661,736 Less: imputed interest (16,380 ) Present value of lease liabilities $ 645,356 Operating lease liability, current $ 455,545 Operating lease liability, net of current portion 189,811 Total operating lease liabilities $ 645,356 Weighted-average remaining lease term (in years) 1.17 Weighted-average discount rate 3.44 % |
Intangible Assets, Net (Tables)
Intangible Assets, Net (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of gross carrying amount and accumulated amortization of separately identifiable intangible assets | As of June 30, 2022 Gross Accumulated Net Carrying Patents $ 60,550 $ (4,614 ) $ 55,936 Trademark 45,000 (18,500 ) 26,500 Rights to intellectual property 100,000 (556 ) 99,444 Total intangible assets $ 205,550 $ (23,670 ) $ 181,880 As of December 31, 2021 Gross Accumulated Net Carrying Patent $ 7,000 $ (4,083 ) $ 2,917 Trademark 45,000 (17,000 ) 28,000 Total intangible assets $ 52,000 $ (21,083 ) $ 30,917 |
Schedule of estimated amortization expense for all intangible assets | Years Ending December 31, Amortization Remainder of 2022 $ 6,852 2023 10,688 2024 10,688 2025 10,688 2026 10,688 Thereafter 132,276 Total $ 181,880 |
Capital Structure (Tables)
Capital Structure (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Capital Structure [Abstract] | |
Schedule of securities into which warrants are convertible | Securities into which warrants are convertible Warrants Exercise Expiration Fair Common stock (Initial Public Offering) 140,000 $ 9.375 October 2026 $ 170,397 Common stock (Private Placement) 6,451,613 $ 2.98 April 2027 $ 6,132,436 Total 6,591,613 $ 6,302,833 |
Schedule of fair value of warrants | Initial Public Offering Private Placement Warrants Warrants Fair value of underlying securities $ 2.88 $ 1.37 Expected volatility 51.0 % 45.0 % Expected term (in years) 5.0 5.0 Risk-free interest rate 1.13 % 2.92 % |
Schedule of authorized, issued and outstanding shares of the convertible preferred stock and liquidation preferences | Series Shares Shares Per Share Aggregate Gross Series A 10,157,843 10,157,843 0.6842 6,949,996 6,949,996 Series B 6,567,670 6,567,670 3.3939 22,290,015 22,290,015 Series C 5,256,978 5,256,978 15.7933 83,025,031 83,025,031 21,982,491 21,982,491 112,265,042 112,265,042 |
Net Loss Per Share Attributab_2
Net Loss Per Share Attributable to Common Stockholders (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of basic and diluted loss per share | Three months ended 2022 2021 Net loss attributable to common stockholders $ (4,611,961 ) $ (2,091,572 ) Basic and diluted weighted average common shares outstanding 30,706,235 951,794 Loss per share: Basic and diluted $ (0.15 ) $ (2.20 ) Six months ended 2022 2021 Net loss attributable to common stockholders $ (8,431,000 ) $ (3,643,395 ) Basic and diluted weighted average common shares outstanding 26,682,245 951,794 Loss per share: Basic and diluted $ (0.29 ) $ (3.83 ) |
Schedule of common stock reserved for future issuance, on an as-if converted basis | June 30, 2022 2021 Issuance of options under stock option plan 9,708,436 5,923,887 Shares available for future stock option grants 8,911,339 10,877,419 Common shares issuable upon conversion of preferred stock - 21,982,491 Total 18,619,775 38,783,797 |
Stock-Based Compensation Expe_2
Stock-Based Compensation Expense (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Stock-Based Compensation Expense Table [Abstract] | |
Schedule of stock options vested and exercisable | Shares Weighted- Weighted- Aggregate Outstanding as of December 31, 2021 8,769,694 $ 1.20 7.15 $ 15,746,916 Granted 1,384,500 1.95 - Exercised (636,041 ) 0.15 - 931,660 Cancelled/forfeited (50,209 ) 2.88 - Outstanding as of June 30, 2022 9,467,944 $ 1.37 7.20 $ 5,082,634 Vested and expected to vest at June 30, 2022 9,467,944 $ 1.37 7.20 $ 5,082,634 Vested and exercisable at June 30, 2022 5,409,688 $ 0.37 5.63 $ 5,019,382 |
Schedule of restricted stock units and activity | Shares Weighted- Unvested shares at December 31, 2021 - $ - RSUs granted 244,566 5.52 RSUs vested (4,074 ) 5.52 RSUs forfeited - - Unvested Shares at June 30, 2022 240,492 $ 5.52 |
Schedule of weighted average fair value of each grant estimated on grant date | Six Months Ended 2022 2021 Fair value of common stock $ 1.95 $ - Expected term (in years) 6.06 - Risk-free rate 2.49 % - % Expected volatility 36.23 % - % Dividend yield 0 % 0 % |
Description of Business (Detail
Description of Business (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 6 Months Ended | |||
Apr. 29, 2022 | Oct. 22, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Description of Business (Details) [Line Items] | |||||
Common stock, shares authorized (in Shares) | 100,000,000 | 100,000,000 | |||
Additional shares of common stock (in Shares) | 525,000 | ||||
Shares authorized (in Shares) | 110,000,000 | ||||
Common stock shares (in Shares) | 100,000,000 | ||||
Preferred stock shares (in Shares) | 10,000,000 | ||||
Preferred stock, per shares (in Dollars per share) | $ 0.00001 | ||||
Stock purchase agreement | Pursuant to the Purchase Agreement, the Company sold (i) 3,790,322 shares of its Common Stock together with Common Warrants to purchase up to 3,790,322 shares of Common Stock, and (ii) 2,661,291 Pre-Funded Warrants with each Pre-Funded Warrant exercisable for one share of Common Stock, together with Common Warrants to purchase up to 2,661,291 shares of Common Stock. | ||||
Common warrants (in Shares) | 6,451,613 | ||||
Exercise price per share (in Dollars per share) | $ 2.98 | ||||
Offering price per share (in Dollars per share) | $ 3.09 | ||||
Exercisable expire term | 5 years | ||||
Net losses | $ 8.4 | $ 3.6 | |||
Accumulated deficit | 125 | $ 116.5 | |||
Net cash used in operating activities | 7 | $ 3.5 | |||
Unrestricted cash and cash equivalents | $ 5.6 | 21.9 | |||
Purchase Warrants [Member] | |||||
Description of Business (Details) [Line Items] | |||||
Redeemable Warrants (in Shares) | 140,000 | ||||
Initial exercise price per share (in Dollars per share) | $ 9.375 | ||||
IPO [Member] | |||||
Description of Business (Details) [Line Items] | |||||
Preferred stock, par value (in Dollars per share) | 0.00001 | ||||
IPO [Member] | Common Stock [Member] | |||||
Description of Business (Details) [Line Items] | |||||
Common stock, shares authorized (in Shares) | 3,500,000 | ||||
Offering price per share (in Dollars per share) | $ 7.5 | ||||
Private Placement [Member] | |||||
Description of Business (Details) [Line Items] | |||||
Gross proceeds | $ 20 | ||||
Private Placement [Member] | Warranr [Member] | |||||
Description of Business (Details) [Line Items] | |||||
Offering price per share (in Dollars per share) | 3.1 | ||||
Exercise price per share (in Dollars per share) | $ 0.001 | ||||
“CYN” [Member] | IPO [Member] | |||||
Description of Business (Details) [Line Items] | |||||
Net proceeds | $ 23.3 | ||||
Liquidity [Member] | |||||
Description of Business (Details) [Line Items] | |||||
Cash and cash equivalents | $ 5.6 | ||||
Unrestricted cash and cash equivalents | $ 21.9 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Details) - USD ($) | Apr. 01, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 5,600,000 | $ 21,900,000 | ||
Restricted cash | $ 50,000 | $ 400,000 | ||
Purchase price of rights | $ 100,000 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details) - Schedule of cash and cash equivalents and restricted cash - USD ($) | Jun. 30, 2022 | Jun. 30, 2021 |
Schedule of cash and cash equivalents and restricted cash [Abstract] | ||
Cash and cash equivalents | $ 5,601,774 | $ 3,404,381 |
Restricted cash | 50,000 | 400,000 |
Total cash and cash equivalents and restricted cash | $ 5,651,774 | $ 3,804,381 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life | 6 Months Ended |
Jun. 30, 2022 | |
Computer and equipment [Member] | |
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life [Line Items] | |
Property and Equipment, Useful Life | 5 years |
Furniture and fixtures [Member] | |
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life [Line Items] | |
Property and Equipment, Useful Life | 7 years |
Leasehold improvements [Member] | |
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life [Line Items] | |
Property and Equipment, Useful Life | Shorter of 3 years or remaining lease term |
Automobile [Member] | |
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life [Line Items] | |
Property and Equipment, Useful Life | 5 years |
Balance Sheet Components (Detai
Balance Sheet Components (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | |
Balance Sheet Components (Details) [Line Items] | ||||||
Net of unrealized holding (loss) | $ 41,233 | |||||
Dividends | 15 | |||||
Depreciation expense | $ 24,330 | $ 22,044 | $ 45,405 | $ 44,086 | ||
Deferred social security taxes | $ 67,958 | |||||
Forecast [Member] | ||||||
Balance Sheet Components (Details) [Line Items] | ||||||
Deferred social security taxes | $ 67,958 |
Balance Sheet Components (Det_2
Balance Sheet Components (Details) - Schedule of level 1 inputs utilizing quoted prices in active markets for identical assets - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Cash and cash equivalents | ||
Cash at banks | $ 5,651,774 | $ 21,995,981 |
Short-term investments, net | ||
U.S. government securities | 26,958,781 | |
Total | 32,610,555 | 21,995,981 |
Level 1 [Member] | ||
Cash and cash equivalents | ||
Cash at banks | 5,651,774 | 21,995,981 |
Short-term investments, net | ||
U.S. government securities | 26,958,781 | |
Total | 32,610,555 | 21,995,981 |
Level 2 [Member] | ||
Cash and cash equivalents | ||
Cash at banks | ||
Short-term investments, net | ||
U.S. government securities | ||
Total | ||
Level 3 [Member] | ||
Cash and cash equivalents | ||
Cash at banks | ||
Short-term investments, net | ||
U.S. government securities | ||
Total |
Balance Sheet Components (Det_3
Balance Sheet Components (Details) - Schedule of property and equipment - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Schedule of property and equipment [Abstract] | ||
Automobiles | $ 361,724 | $ 279,617 |
Furniture and fixtures | 139,501 | 133,102 |
Computer and equipment | 276,257 | 76,048 |
Construction work in progress | 121,574 | |
Property and equipment, gross | 899,056 | 488,767 |
Less: accumulated depreciation | (431,385) | (385,980) |
Total property and equipment, net | $ 467,671 | $ 102,787 |
Balance Sheet Components (Det_4
Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Schedule of accrued expenses and other current liabilities [Abstract] | ||
Credit card payable | $ 6,750 | $ 11,678 |
Accrued expenses | 138,734 | 82,478 |
Accrued payroll | 241,121 | 201,000 |
Total accrued expenses and other current liabilities | $ 386,605 | $ 295,156 |
Leases (Details)
Leases (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Leases [Abstract] | ||||
Rent expense | $ 47,000 | |||
Operating lease | $ 157,869 | $ 75,287 | 235,968 | $ 114,882 |
Operating lease right-of-use assets | $ 133,998 | $ 0 | $ 181,110 | $ 0 |
Leases (Details) - Schedule of
Leases (Details) - Schedule of future lease payments under non-cancellable leases | Jun. 30, 2022 USD ($) |
Schedule of future lease payments under non-cancellable leases [Abstract] | |
Remainder of 2022 | $ 279,410 |
2023 | 382,326 |
Total lease payments | 661,736 |
Less: imputed interest | (16,380) |
Present value of lease liabilities | 645,356 |
Operating lease liability, current | 455,545 |
Operating lease liability, net of current portion | 189,811 |
Total operating lease liabilities | $ 645,356 |
Weighted-average remaining lease term (in years) | 1 year 2 months 1 day |
Weighted-average discount rate | 3.44% |
Intangible Assets, Net (Details
Intangible Assets, Net (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||||
Amortization expense | $ 1,720 | $ 866 | $ 2,587 | $ 1,733 |
Intangible Assets, Net (Detai_2
Intangible Assets, Net (Details) - Schedule of gross carrying amount and accumulated amortization of separately identifiable intangible assets - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 205,550 | $ 52,000 |
Accumulated Amortization | (23,670) | (21,083) |
Net Carrying Amount | 181,880 | 30,917 |
Patents [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 60,550 | 7,000 |
Accumulated Amortization | (4,614) | (4,083) |
Net Carrying Amount | 55,936 | 2,917 |
Trademark [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 45,000 | 45,000 |
Accumulated Amortization | (18,500) | (17,000) |
Net Carrying Amount | 26,500 | $ 28,000 |
Rights to intellectual property [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 100,000 | |
Accumulated Amortization | (556) | |
Net Carrying Amount | $ 99,444 |
Intangible Assets, Net (Detai_3
Intangible Assets, Net (Details) - Schedule of estimated amortization expense for all intangible assets - Amortization [Member] | Jun. 30, 2022 USD ($) |
Intangible Assets, Net (Details) - Schedule of estimated amortization expense for all intangible assets [Line Items] | |
Remainder of 2022 | $ 6,852 |
2023 | 10,688 |
2024 | 10,688 |
2025 | 10,688 |
2026 | 10,688 |
Thereafter | 132,276 |
Total | $ 181,880 |
Debt (Details)
Debt (Details) - USD ($) | Feb. 28, 2021 | Apr. 30, 2020 |
Debt Disclosure [Abstract] | ||
Company borrowings | $ 695,078 | |
Interest rate | 0.98% | |
Maturity date | 5 years | 24 months |
Principal amount | $ 892,115 | |
Interest accruing | 0.98% |
Capital Structure (Details)
Capital Structure (Details) - $ / shares | Jun. 30, 2022 | Dec. 31, 2021 | Oct. 31, 2021 | Jun. 30, 2021 |
Capital Structure (Details) [Line Items] | ||||
Common stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 | ||
Common stock, shares issued | 33,575,334 | 33,575,334 | ||
Common stock, shares outstanding | 26,487,680 | 26,487,680 | ||
Preferred stock, shares authorized | 21,982,491 | |||
Preferred stock, par value (in Dollars per share) | $ 0.00001 | |||
Common Stock [Member] | ||||
Capital Structure (Details) [Line Items] | ||||
Common stock, shares authorized | 100,000,000 | 100,000,000 | ||
Common stock, par value (in Dollars per share) | $ 0.00001 | |||
Convertible Preferred Stock [Member] | ||||
Capital Structure (Details) [Line Items] | ||||
Convertible preferred stock, shares authorized | 10,000,000 | |||
Preferred stock, par value (in Dollars per share) | $ 0.00001 | |||
Series A [Member] | ||||
Capital Structure (Details) [Line Items] | ||||
Convertible preferred stock, shares authorized | 10,000,000 | 10,000,000 | ||
Preferred stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 | ||
Dividends declared on common stock, per share (in Dollars per share) | $ 0.0411 | |||
Series B [Member] | ||||
Capital Structure (Details) [Line Items] | ||||
Convertible preferred stock, shares authorized | 10,000,000 | 10,000,000 | ||
Preferred stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 | ||
Dividends declared on common stock, per share (in Dollars per share) | $ 0.2036 | |||
Series C [Member] | ||||
Capital Structure (Details) [Line Items] | ||||
Convertible preferred stock, shares authorized | 10,000,000 | 10,000,000 | ||
Preferred stock, par value (in Dollars per share) | $ 0.00001 | $ 0.00001 | ||
Dividends declared on common stock, per share (in Dollars per share) | $ 0.9476 |
Capital Structure (Details) - S
Capital Structure (Details) - Schedule of securities into which warrants are convertible | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 $ / shares shares | Jun. 30, 2022 shares | |
Common Stock [Member] | ||
Capital Structure (Details) - Schedule of securities into which warrants are convertible [Line Items] | ||
Warrants outstanding | 140,000 | 170,397 |
Exercise Price (in Dollars per share) | $ / shares | $ 9.375 | |
Expiration Date | October 2026 | October 2026 |
Common Stock [Member] | ||
Capital Structure (Details) - Schedule of securities into which warrants are convertible [Line Items] | ||
Warrants outstanding | 6,451,613 | 6,132,436 |
Exercise Price (in Dollars per share) | $ / shares | $ 2.98 | |
Expiration Date | April 2027 | April 2027 |
Total [Member] | ||
Capital Structure (Details) - Schedule of securities into which warrants are convertible [Line Items] | ||
Warrants outstanding | 6,591,613 | 6,302,833 |
Capital Structure (Details) -_2
Capital Structure (Details) - Schedule of fair value of warrants | 6 Months Ended |
Jun. 30, 2022 USD ($) | |
Initial Public Offering Warrants [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Fair value of underlying securities (in Dollars) | $ 2.88 |
Expected volatility | 51% |
Expected term (in years) | 5 years |
Risk-free interest rate | 1.13% |
Private Placement Warrants [Member] | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |
Fair value of underlying securities (in Dollars) | $ 1.37 |
Expected volatility | 45% |
Expected term (in years) | 5 years |
Risk-free interest rate | 2.92% |
Capital Structure (Details) -_3
Capital Structure (Details) - Schedulezed, issued and outstanding shares of convertible preferred stock and liquidation preferences | 6 Months Ended |
Jun. 30, 2022 USD ($) $ / shares shares | |
Conversion of Stock [Line Items] | |
Shares Authorized | shares | 21,982,491 |
Shares Issued and Outstanding | shares | 21,982,491 |
Aggregate Liquidation Amount | $ | $ 112,265,042 |
Gross Proceeds | $ | $ 112,265,042 |
Series A [Member] | |
Conversion of Stock [Line Items] | |
Shares Authorized | shares | 10,157,843 |
Shares Issued and Outstanding | shares | 10,157,843 |
Per Share Liquidation Preference | $ / shares | $ 0.6842 |
Aggregate Liquidation Amount | $ | $ 6,949,996 |
Gross Proceeds | $ | $ 6,949,996 |
Series B [Member] | |
Conversion of Stock [Line Items] | |
Shares Authorized | shares | 6,567,670 |
Shares Issued and Outstanding | shares | 6,567,670 |
Per Share Liquidation Preference | $ / shares | $ 3.3939 |
Aggregate Liquidation Amount | $ | $ 22,290,015 |
Gross Proceeds | $ | $ 22,290,015 |
Series C [Member] | |
Conversion of Stock [Line Items] | |
Shares Authorized | shares | 5,256,978 |
Shares Issued and Outstanding | shares | 5,256,978 |
Per Share Liquidation Preference | $ / shares | $ 15.7933 |
Aggregate Liquidation Amount | $ | $ 83,025,031 |
Gross Proceeds | $ | $ 83,025,031 |
Net Loss Per Share Attributab_3
Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted loss per share - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Schedule of basic and diluted loss per share [Abstract] | ||||
Net loss attributable to common stockholders | $ (4,611,961) | $ (2,091,572) | $ (8,431,000) | $ (3,643,395) |
Basic and diluted weighted average common shares outstanding | 30,706,235 | 951,794 | 26,682,245 | 951,794 |
Basic and diluted | $ (0.15) | $ (2.2) | $ (0.29) | $ (3.83) |
Net Loss Per Share Attributab_4
Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of common stock reserved for future issuance, on an as-if converted basis - USD ($) | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Schedule of common stock reserved for future issuance, on an as-if converted basis [Abstract] | ||
Issuance of options under stock option plan (in Dollars) | $ 9,708,436 | $ 5,923,887 |
Shares available for future stock option grants | 8,911,339 | 10,877,419 |
Common shares issuable upon conversion of preferred stock | 21,982,491 | |
Total | 18,619,775 | 38,783,797 |
Stock-Based Compensation Expe_3
Stock-Based Compensation Expense (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Stock-Based Compensation Expense (Details) [Line Items] | ||||
Fair value is recognized straight-line basis, description | The resulting fair value is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award. The Company has elected to recognize forfeitures as they occur. Stock options generally vest over four years and have a contractual term of ten years. | |||
Common stock issuance (in Shares) | 8,911,339 | 10,502,696 | ||
Weighted average per share grant-date fair value of options granted (in Dollars per share) | $ 0.77 | $ 0 | ||
Stock-based compensation expense from stock options | $ 713,570 | $ 1,233,712 | $ 88,198 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price (in Dollars per share) | $ 96,058 | |||
Weighted-average period | 3 years 8 months 12 days | |||
Stock Options [Member] | ||||
Stock-Based Compensation Expense (Details) [Line Items] | ||||
Stock-based compensation unrecognized unvested stock options | $ 8,112,136 | |||
Unvested RSUs [Member] | ||||
Stock-Based Compensation Expense (Details) [Line Items] | ||||
Stock-based compensation unrecognized unvested stock options | $ 8,112,136 |
Stock-Based Compensation Expe_4
Stock-Based Compensation Expense (Details) - Schedule of stock options vested and exercisable | 6 Months Ended |
Jun. 30, 2022 USD ($) $ / shares shares | |
Schedule of stock options vested and exercisable [Abstract] | |
Shares, outstanding at beginning balance | shares | 8,769,694 |
Weighted- average exercise price, outstanding at beginning balance | $ / shares | $ 1.2 |
Weighted- average remaining contractual term (years), outstanding at beginning balance | 7 years 1 month 24 days |
Aggregate intrinsic value, outstanding at beginning balance | $ | $ 15,746,916 |
Shares, granted | shares | 1,384,500 |
Weighted- average exercise price, granted | $ / shares | $ 1.95 |
Weighted- average remaining contractual term (years), granted | |
Shares ,exercised | shares | (636,041) |
Weighted- average exercise price, exercised | $ / shares | $ 0.15 |
Weighted- average remaining contractual term (years), exercised | |
Aggregate intrinsic value, exercised | $ | $ 931,660 |
Shares, cancelled/forfeited | shares | (50,209) |
Weighted- average exercise price, cancelled/forfeited | $ / shares | $ 2.88 |
Weighted- average remaining contractual term (years), cancelled/forfeited | |
Shares, outstanding at ending balance | shares | 9,467,944 |
Weighted- average exercise price, outstanding at ending balance | $ / shares | $ 1.37 |
Weighted- average remaining contractual term (years), outstanding at ending balance | 7 years 2 months 12 days |
Aggregate intrinsic value, outstanding at ending balance | $ | $ 5,082,634 |
Shares, vested and expected to vest at ending balance | shares | 9,467,944 |
Weighted- average exercise price, vested and expected to vest at ending balance | $ / shares | $ 1.37 |
Weighted- average remaining contractual term (years), vested and expected to vest at ending balance | 7 years 2 months 12 days |
Aggregate intrinsic value, vested and expected to vest at ending balance | $ | $ 5,082,634 |
Shares, vested and exercisable at ending balance | shares | 5,409,688 |
Weighted- average exercise price, vested and exercisable at ending balance | $ / shares | $ 0.37 |
Weighted- average remaining contractual term (years), vested and exercisable at ending balance | 5 years 7 months 17 days |
Aggregate intrinsic value, vested and exercisable at ending balance | $ | $ 5,019,382 |
Stock-Based Compensation Expe_5
Stock-Based Compensation Expense (Details) - Schedule of restricted stock units and activity | 6 Months Ended |
Jun. 30, 2022 $ / shares shares | |
Schedule of restricted stock units and activity [Abstract] | |
Shares, Unvested shares beginning balance | shares | |
Weighted- average grant date fair value, beginning balance | $ / shares | |
Shares, RSUs granted | shares | 244,566 |
Weighted- average grant date fair value, RSUs granted | $ / shares | $ 5.52 |
Shares, RSUs vested | shares | (4,074) |
Weighted- average grant date fair value, RSUs vested | $ / shares | $ 5.52 |
Shares, RSUs forfeited | shares | |
Weighted- average grant date fair value, | $ / shares | |
Shares, ending balance | shares | 240,492 |
Weighted- average grant date fair value, ending balance | $ / shares | $ 5.52 |
Stock-Based Compensation Expe_6
Stock-Based Compensation Expense (Details) - Schedule of weighted average fair value of each grant estimated on grant date - $ / shares | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Schedule of weighted average fair value of each grant estimated on grant date [Abstract] | ||
Fair value of common stock (in Dollars per share) | $ 1.95 | |
Expected term (in years) | 6 years 21 days | |
Risk-free rate | 2.49% | |
Expected volatility | 36.23% | |
Dividend yield | 0% | 0% |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Mar. 27, 2020 | |
Income Taxes (Details) [Line Items] | |||||
Income tax expense (in Dollars) | $ 0 | $ 0 | $ 0 | $ 0 | |
Federal statutory income tax rate | 0% | 0% | 0% | 0% | |
Minimum [Member] | CARES Act [Member] | |||||
Income Taxes (Details) [Line Items] | |||||
Cumulative ownership, percentage | 80% | ||||
Maximum [Member] | CARES Act [Member] | |||||
Income Taxes (Details) [Line Items] | |||||
Cumulative ownership, percentage | 100% |